“ambr15 for cell culture process optimization” Webinar 3P Biopharmaceuticals and Sartorius Stedim Biotech

Did you miss our webinar about our experience using ambr® 15 with CHO-S cell line for the production of monoclonal antibodies?

High-throughput media and feed screening for cell culture process optimization with multi-parallel micro bioreactors

In the development and delivery of high quality therapeutic proteins, high throughput process development tools can really accelerate early process understanding. ambr® 15 cell culture system offers an alternative approach to shake flask or conventional benchtop bioreactors in an automated, multi-parallel, high throughput format. The system can be implemented within the Upstream process workflow to generate early process development data at the small scale with very low demands on operator time, set-up and turn around due to automation and single-use components, and improve global costs of development due to the minimum scale the equipment is designed to operate. In this webinar Dr Marta Ruiz Guillén, USP development expert at 3P Biopharmaceuticals, and Javier Lobo, Field Marketing Manager for Sartorius Stedim Biotech in Latin America, Spain & Portugal; discuss the methods and results from performing media and feed screening evaluations in ambr® 15 with CHO-S cell line producing monoclonal antibodies and demonstrate the effectiveness of ambr 15 for rapid and robust cell culture process development. Watch it now and learn more about the experiments performed:

  • Screening of different media
  • Evaluation of different feeds
  • Effect of supplements
  • Optimization of feed strategy

Our dedicated team of specialists will be happy to discuss any of your Biopharmaceutical Manufacturing needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals lands in the United States.

Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

Published: 2nd May 2023
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.